Kanis J A, Hamdy N A, Cundy T
Ann Med Interne (Paris). 1986;137(3):193-9.
Considerable confusion arises in defining osteomalacia in the presence of renal disease. There are no radiographic or biochemical features which satisfactorily identify all patients with osteomalacia. Histological definitions need to distinguish increased amounts of osteoid due to defective mineralisation from that due to increased bone turnover, both of which may coexist in chronic renal failure. The pathogenesis of osteomalacia in renal failure is multifactorial and not always due to defective metabolism of vitamin D. Deficient production of 25-hydroxyvitamin D may occur because of nutritional privation or urinary losses in the nephrotic syndrome, but these are rare causes of osteomalacia in patients on haemodialysis treatment. It is not clear to what extent defective production of calcitriol, characteristic of end-stage chronic renal failure is causally related to osteomalacia, in part due to uncertainties as to whether vitamin D acts directly on bone to promote mineralisation or whether its effects are mediated indirectly by modulating calcium and phosphate transport at other sites. Following the institution of renal replacement therapy, the incidence of osteomalacia varies markedly between renal units due to the skeletal retention of aluminium caused by the contamination of dialysis fluid or by the chronic ingestion of aluminium-containing phosphate binding agents. This form of osteomalacia is associated with a high risk of fracture, probably more related to depressed bone formation than to the presence of osteomalacia. Rarer causes of osteomalacia include parathyroidectomy and calcium and phosphate deficiency.
在存在肾脏疾病的情况下,定义骨软化症会产生相当大的混淆。没有任何影像学或生化特征能够令人满意地识别所有骨软化症患者。组织学定义需要区分由于矿化缺陷导致的类骨质增多与由于骨转换增加导致的类骨质增多,这两种情况可能同时存在于慢性肾衰竭中。肾衰竭时骨软化症的发病机制是多因素的,并不总是由于维生素D代谢缺陷。25-羟维生素D生成不足可能是由于营养缺乏或肾病综合征中的尿丢失,但这些是血液透析治疗患者骨软化症的罕见原因。尚不清楚终末期慢性肾衰竭特有的骨化三醇生成缺陷在多大程度上与骨软化症存在因果关系,部分原因是关于维生素D是直接作用于骨骼促进矿化,还是其作用通过调节其他部位的钙和磷转运间接介导存在不确定性。在开始肾脏替代治疗后,由于透析液污染或长期摄入含铝的磷酸盐结合剂导致铝在骨骼中潴留,不同肾脏单位骨软化症的发生率差异显著。这种形式的骨软化症与骨折风险高相关,可能更多地与骨形成受抑制有关,而非与骨软化症的存在有关。骨软化症的罕见原因包括甲状旁腺切除术以及钙和磷缺乏。